Calcium and phosphate balance with quotidian hemodialysis
- PMID: 12830440
- DOI: 10.1016/s0272-6386(03)00534-1
Calcium and phosphate balance with quotidian hemodialysis
Abstract
Background: Conventional hemodialysis (HD) is associated with profound disturbances in calcium and phosphate metabolism and abnormal parathyroid hormone (PTH) levels. Effects of more frequent HD on calcium and phosphate balance have not been fully elucidated.
Methods: The London Daily/Nocturnal Hemodialysis Study examined effects of quotidian HD, either daily HD (n = 11) or nocturnal HD (n = 12), on calcium and phosphate metabolism, bone alkaline phosphatase levels, and intact PTH (iPTH) levels.
Results: Daily HD patients showed a slight decrease in predialysis serum phosphate levels, no changes in phosphate-binder requirements or serum calcium levels, and slight increases in serum bone alkaline phosphatase and iPTH levels. Nocturnal HD patients showed a trend for decreased predialysis phosphate levels, with significantly lower values than daily HD and matched control patients on conventional HD therapy at several times. Phosphate-binder use by nocturnal HD patients was significantly reduced. Both quotidian HD groups showed decreases in calcium x phosphate product, with significantly lower values for nocturnal HD patients (38.11 mg(2)/dL(2)) compared with daily HD and control patients (53.99 and 52.51 mg(2)/dL(2), respectively) at 18 months. Bone alkaline phosphatase levels increased slightly and attained statistical significance compared with baseline values for both quotidian HD groups. A trend for increases in serum iPTH levels, coupled with increasing levels of bone alkaline phosphatase in nocturnal HD patients, led to the decision to increase the dialysate calcium concentration from 5.0 to 7.0 mg/dL. This 1-time adjustment resulted in a reversal of the trend and a return to baseline values.
Conclusion: This study shows the superior control of serum phosphate levels in nocturnal HD patients compared with daily HD or conventional HD patients and the benefits of dialysate with a greater calcium concentration in slow nocturnal HD.
Similar articles
-
Nocturnal but not short hours quotidian hemodialysis requires an elevated dialysate calcium concentration.J Am Soc Nephrol. 2003 Sep;14(9):2322-8. doi: 10.1097/01.asn.0000083044.42480.c1. J Am Soc Nephrol. 2003. PMID: 12937309
-
The impact of quotidian hemodialysis on nutrition.Am J Kidney Dis. 2003 Jul;42(1 Suppl):30-5. doi: 10.1016/s0272-6386(03)00535-3. Am J Kidney Dis. 2003. PMID: 12830441 Clinical Trial.
-
Management of anemia with quotidian hemodialysis.Am J Kidney Dis. 2003 Jul;42(1 Suppl):18-23. doi: 10.1016/s0272-6386(03)00533-x. Am J Kidney Dis. 2003. PMID: 12830439 Clinical Trial.
-
Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.Am J Kidney Dis. 2016 Nov;68(5S1):S24-S32. doi: 10.1053/j.ajkd.2016.05.024. Am J Kidney Dis. 2016. PMID: 27772640 Review.
-
Restoration of parathyroid function after change of phosphate binder from calcium carbonate to lanthanum carbonate in hemodialysis patients with suppressed serum parathyroid hormone.J Ren Nutr. 2015 Mar;25(2):242-6. doi: 10.1053/j.jrn.2014.10.013. Epub 2014 Dec 30. J Ren Nutr. 2015. PMID: 25556148 Review.
Cited by
-
The role of short daily hemodialysis in the control of hyperphosphatemia, secondary hyperparathyroidism and anemia.Int Urol Nephrol. 2013 Dec;45(6):1725-31. doi: 10.1007/s11255-013-0441-z. Epub 2013 Apr 17. Int Urol Nephrol. 2013. PMID: 23591723
-
Control of hyperphosphatemia and maintenance of calcemia in CKD.J Bras Nefrol. 2021 Dec 3;43(4 Suppl 1):632-638. doi: 10.1590/2175-8239-JBN-2021-S105. eCollection 2021. J Bras Nefrol. 2021. PMID: 34910797 Free PMC article. No abstract available.
-
The Impact of Medication Regimen Complexity on Patient-Related and Clinical Outcomes in Patients Undergoing Hemodialysis.Hemodial Int. 2025 Apr;29(2):231-236. doi: 10.1111/hdi.13214. Epub 2025 Feb 23. Hemodial Int. 2025. PMID: 39988911 Free PMC article.
-
Effects of frequent hemodialysis on measures of CKD mineral and bone disorder.J Am Soc Nephrol. 2012 Apr;23(4):727-38. doi: 10.1681/ASN.2011070688. Epub 2012 Feb 23. J Am Soc Nephrol. 2012. PMID: 22362907 Free PMC article. Clinical Trial.
-
Extended release nicotinic acid - a novel oral agent for phosphate control.Int Urol Nephrol. 2006;38(1):171-4. doi: 10.1007/s11255-006-0001-x. Int Urol Nephrol. 2006. PMID: 16502077 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical